Related Experiment Videos
Problems in the design of anticancer agents
M D'Incalci1, G Balconi, M Broggini
1Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
Abstract:
Theoretically, two predominant paths for obtaining more selective anticancer agents may be envisaged. These are: (a) to make compounds which distribute only or preferentially in cancer cells; (b) to make compounds that are able selectively to kill or to differentiate cancer cells. Although in the last two decades research into new anticancer drugs has not produced satisfactory results, there is solid ground on which novel strategies can be developed, mainly based on a much greater biological knowledge of human tumours. This article does not review all the possible approaches that may be followed, but simply discusses some ideas and problems mainly taken from the current research of our laboratory.
Insights
Developing selective anticancer agents involves targeting cancer cells for distribution or selective killing. Novel strategies leverage increased biological knowledge of human tumors for improved cancer therapies.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Anticancer drug development has faced challenges in recent decades.
- Significant advancements in understanding human tumor biology provide a foundation for new strategies.
Purpose of the Study:
- To explore theoretical approaches for developing more selective anticancer agents.
- To discuss current research ideas and challenges in anticancer drug discovery.
Main Methods:
- Focus on two primary strategies: preferential drug distribution to cancer cells and selective cancer cell killing or differentiation.
- Discussion of concepts derived from laboratory's current research.
Main Results:
- Identified two main theoretical pathways for enhancing anticancer agent selectivity.
- Highlighted the importance of biological knowledge in guiding novel therapeutic strategies.
Conclusions:
- Greater biological insight into human tumors is crucial for developing next-generation anticancer drugs.
- Future anticancer therapies may benefit from targeted delivery or selective action mechanisms.